Form 6 1-Year Post-TED

Post-Transplant Essential Data

OMB No: 0915-0310
Expiration Date: 1/31/2020

Registry Use Only
Sequence Number:

Public Burden Statement: An agency may not conduct or sponsor, and a person is
not required to respond to, a collection of information unless it displays a currently
valid OMB control number. The OMB control number for this project is 0915-0310.
Public reporting burden for this collection of information is estimated to average
0.85 hours per response when collected at 100 days post-transplant, 1.0 hours per
response when collected at 6 and 12 months post-transplant, and 1.5 hours per
response annually thereafter, including the time for reviewing instructions, searching
existing data sources, and completing and reviewing the collection of information.
Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to HRSA Reports
Clearance Officer, 5600 Fishers Lane, Room 10-33, Rockville, Maryland, 20857.
Expiration date: 1/31/2020

Date Received:

CIBMTR Center Number: ___ ___ ___ ___ ___
CIBMTR Research ID: ___ ___ ___ ___ ___ ___ ___ ___ ___ ___
Event date: __ __ __ __ / __ __ / __ __

YYYY
MM
DD
Visit: ☐ 100 day

☐ 6 months

☐ 1 year

☐ 2 years

☐ >2 years. Specify: ___ ___

CIBMTR Form 2450 revision 5 (page 1 of 16). Last Updated November, 2018.
Copyright (c) 2018 National Marrow Donor Program and
The Medical College of Wisconsin, Inc. All rights reserved.

CIBMTR Center Number: ___ ___ ___ ___ ___

CIBMTR Research ID: ___ ___ ___ ___ ___ ___ ___ ___ ___ ___

Survival
1.

Date of actual contact with the recipient to determine medical status for this follow-up report: __ __ __ __ / __ __ / __ __
YYYY
MM
DD

2.

Specify the recipient’s survival status at the date of last contact

☐ Alive – Answers to subsequent questions should reflect clinical status since the date of last report. - Go to question 7
☐ Dead – Answers to subsequent questions should reflect clinical status between the date of last report and immediately prior to

death. - Go to question 3
3.

Primary cause of death

☐ Acute GVHD - Go to question 5
☐ Chronic GVHD - Go to question 5
☐ Graft rejection or failure - Go to question 5
☐ Cytokine release syndrome - Go to question 5

☐ Recurrence / persistence / progression of disease for which the HCT or cellular therapy was performed

- Go to question 5

Infection

☐ Infection, organism not identified - Go to question 5
☐ Bacterial infection - Go to question 5
☐ Fungal infection - Go to question 5
☐ Viral infection - Go to question 5
☐ Protozoal infection - Go to question 5
☐ Other infection - Go to question 4

Pulmonary

☐ Idiopathic pneumonia syndrome (IPS) - Go to question 5
☐ Pneumonitis due to Cytomegalovirus (CMV) - Go to question 5
☐ Pneumonitis due to other virus - Go to question 5
☐ Other pulmonary syndrome (excluding pulmonary hemorrhage) - Go to question 4
☐ Diffuse alveolar damage (without hemorrhage) - Go to question 5
☐ Acute respiratory distress syndrome (ARDS) (other than IPS) - Go to question 5

Organ failure (not due to GVHD or infection)

☐ Liver failure (not VOD) - Go to question 5
☐ Veno-occlusive disease (VOD) / sinusoidal obstruction syndrome (SOS) - Go to question 5
☐ Cardiac failure - Go to question 5
☐ Pulmonary failure - Go to question 5
☐ Central nervous system (CNS) failure - Go to question 5
☐ Renal failure - Go to question 5
☐ Gastrointestinal (GI) failure (not liver) - Go to question 5
☐ Multiple organ failure - Go to question 4
☐ Other organ failure - Go to question 4

Malignancy

☐ New malignancy (post-HCT or post-cellular therapy) - Go to question 5

☐ Prior malignancy (malignancy initially diagnosed prior to HCT or cellular therapy, other than the
malignancy for which the HCT or cellular therapy was performed) - Go to question 5

CIBMTR Form 2450 revision 5 (page 2 of 16). Last Updated November, 2018.
Copyright (c) 2018 National Marrow Donor Program and
The Medical College of Wisconsin, Inc. All rights reserved.

CIBMTR Center Number: ___ ___ ___ ___ ___

CIBMTR Research ID: ___ ___ ___ ___ ___ ___ ___ ___ ___ ___

Hemorrhage

☐ Pulmonary hemorrhage - Go to question 5
☐ Diffuse alveolar hemorrhage (DAH) - Go to question 5
☐ Intracranial hemorrhage - Go to question 5
☐ Gastrointestinal hemorrhage - Go to question 5
☐ Hemorrhagic cystitis - Go to question 5
☐ Other hemorrhage - Go to question 4

Vascular

☐ Thromboembolic - Go to question 5
☐ Disseminated intravascular coagulation (DIC) - Go to question 5
☐ Thrombotic microangiopathy (TMA) (Thrombotic thrombocytopenic purpura (TTP)/Hemolytic Uremic

Syndrome (HUS)) - Go to question 5

☐ Other vascular - Go to question 4

Other

☐ Accidental death - Go to question 5
☐ Suicide - Go to question 5
☐ Other cause - Go to question 4
4. Specify:____________________________________________________________

5.

Contributing cause of death: (check all that apply)

☐ Acute GVHD - Go to question 7
☐ Chronic GVHD - Go to question 7
☐ Graft rejection or failure - Go to question 7
☐ Cytokine release syndrome - Go to question 7

☐ Recurrence / persistence / progression of disease for which the HCT or cellular therapy was performed

- Go to question 7

Infection

☐ Infection, organism not identified - Go to question 7
☐ Bacterial infection - Go to question 7
☐ Fungal infection - Go to question 7
☐ Viral infection - Go to question 7
☐ Protozoal infection - Go to question 7
☐ Other infection - Go to question 6

Pulmonary

☐ Idiopathic pneumonia syndrome (IPS) - Go to question 7
☐ Pneumonitis due to Cytomegalovirus (CMV) - Go to question 7
☐ Pneumonitis due to other virus - Go to question 7
☐ Other pulmonary syndrome (excluding pulmonary hemorrhage) - Go to question 6
☐ Diffuse alveolar damage (without hemorrhage) - Go to question 7
☐ Acute respiratory distress syndrome (ARDS) (other than IPS) - Go to question 7

Organ failure (not due to GVHD or infection)

☐ Liver failure (not VOD) - Go to question 7

CIBMTR Form 2450 revision 5 (page 3 of 16). Last Updated November, 2018.
Copyright (c) 2018 National Marrow Donor Program and
The Medical College of Wisconsin, Inc. All rights reserved.

CIBMTR Center Number: ___ ___ ___ ___ ___

CIBMTR Research ID: ___ ___ ___ ___ ___ ___ ___ ___ ___ ___

☐ Veno-occlusive disease (VOD) / sinusoidal obstruction syndrome (SOS) - Go to question 7
☐ Cardiac failure - Go to question 7
☐ Pulmonary failure - Go to question 7
☐ Central nervous system (CNS) failure - Go to question 7
☐ Renal failure - Go to question 7
☐ Gastrointestinal (GI) failure (not liver) - Go to question 7
☐ Multiple organ failure - Go to question 6
☐ Other organ failure - Go to question 6

Malignancy

☐ New malignancy (post-HCT or post-cellular therapy) - Go to question 7

☐ Prior malignancy (malignancy initially diagnosed prior to HCT or cellular therapy, other than the
malignancy for which the HCT or cellular therapy was performed) - Go to question 7
Hemorrhage

☐ Pulmonary hemorrhage - Go to question 7
☐ Diffuse alveolar hemorrhage (DAH) - Go to question 7
☐ Intracranial hemorrhage - Go to question 7
☐ Gastrointestinal hemorrhage - Go to question 7
☐ Hemorrhagic cystitis - Go to question 7
☐ Other hemorrhage - Go to question 6

Vascular

☐ Thromboembolic - Go to question 7
☐ Disseminated intravascular coagulation (DIC) - Go to question 7
☐ Thrombotic microangiopathy (TMA) (Thrombotic thrombocytopenic purpura (TTP)/Hemolytic Uremic

Syndrome (HUS)) - Go to question 7

☐ Other vascular - Go to question 6

Other

☐ Accidental death - Go to question 7
☐ Suicide - Go to question 7
☐ Other cause - Go to question 6
6. Specify:____________________________________________________________

CIBMTR Form 2450 revision 5 (page 4 of 16). Last Updated November, 2018.
Copyright (c) 2018 National Marrow Donor Program and
The Medical College of Wisconsin, Inc. All rights reserved.

CIBMTR Center Number: ___ ___ ___ ___ ___

CIBMTR Research ID: ___ ___ ___ ___ ___ ___ ___ ___ ___ ___

Subsequent Transplant
7.

Did the recipient receive a subsequent HCT since the date of last report?

☐ Yes
☐ No

8.

Date of subsequent HCT: __ __ __ __ / __ __ / __ __
YYYY
MM
DD

9.

What was the indication for subsequent HCT?

☐ Graft failure / insufficient hematopoietic recovery – Allogeneic HCTs Complete a Pre-TED Form 2400
for the subsequent HCT - Go to question 11

☐ Persistent primary disease – Complete a Pre-TED Form 2400 for the subsequent HCT

- Go to question 11

☐ Recurrent primary disease – Complete a Pre-TED Form 2400 for the subsequent HCT
- Go to question 11

☐ Planned second HCT, per protocol – Complete a Pre-TED Form 2400 for the subsequent HCT
- Go to question 11

☐ New malignancy (including PTLD and EBV lymphoma) – Complete a Pre-TED Form 2400 for the
subsequent HCT - Go to question 11

☐ Insufficient chimerism – Complete a Pre-TED Form 2400 for the subsequent HCT
- Go to question 11

☐ Other – Complete a Pre-TED Form 2400 for the subsequent HCT - Go to question 10
10. Specify other indication: ________________________________________________

11.

Source of HSCs

☐ Allogeneic, related

☐ Allogeneic, unrelated

☐ Autologous

12. Has the recipient received a cellular therapy since the date of last report? (e.g. CAR-T, DCI)

☐ Yes – Also complete Cellular Therapy Essential Data Pre-Infusion Form 4000
☐ No
13. Date of cellular therapy: __ __ __ __ / __ __ / __ __

YYYY
MM
DD

Initial ANC Recovery
14. Was there evidence of initial hematopoietic recovery?

☐ Yes (ANC ≥ 500/mm achieved and sustained for 3 lab values) - Go to question 15
☐ No (ANC ≥ 500/mm was not achieved) - Go to question 16
☐ Not applicable (ANC never dropped below 500/mm at any time after the start of the preparative regimen) - Go to question 16
☐ Previously reported (Recipient’s initial hematopoietic recovery was recorded on a previous report) - Go to question 16
3

3

3

15. Date ANC ≥ 500/mm3 (first of 3 lab values): __ __ __ __ / __ __ / __ __

YYYY
MM
DD
16. Did late graft failure occur?

☐ Yes

☐ No

CIBMTR Form 2450 revision 5 (page 5 of 16). Last Updated November, 2018.
Copyright (c) 2018 National Marrow Donor Program and
The Medical College of Wisconsin, Inc. All rights reserved.

CIBMTR Center Number: ___ ___ ___ ___ ___

CIBMTR Research ID: ___ ___ ___ ___ ___ ___ ___ ___ ___ ___

Initial Platelet Recovery
(Optional for Non-U.S. Centers)
17. Was an initial platelet count ≥ 20 x 109/L achieved?

☐ Yes - Go to question 18
☐ No - Go to question 19
☐ Not applicable - Platelet count never dropped below 20 x 10 /L - Go to question 19
☐ Previously reported - ≥ 20 x 10 /L was achieved and reported previously - Go to question 19
9

9

18.

Date platelets ≥ 20 x 109/L: __ __ __ __ / __ __ / __ __
YYYY
MM
DD

Graft vs. Host Disease
This section is for allogeneic HCTs only. If this was an autologous HCT, continue to Liver Toxicity Prophylaxis, question 45.
19. Did acute GVHD develop since the date of last report?

☐ Yes
☐ No
☐ Unknown

20. Date of acute GVHD diagnosis: __ __ __ __ / __ __ / __ __ - Go to question 22

YYYY
MM
DD

21. Did acute GVHD persist since the date of last report?

☐ Yes
☐ No
☐ Unknown

22. Overall grade of acute GVHD at diagnosis:

☐ I - Rash on ≤ 50% of skin, no liver or gut involvement

☐ II - Rash on > 50% of skin, bilirubin 2-3 mg/dL, or diarrhea 500-1000 mL/day or
persistent nausea

☐ III - Bilirubin 3-15 mg/dL, or gut stage 2-4 diarrhea > 1000 mL/day or severe
abdominal pain with or without ileus

☐ IV - Generalized erythroderma with bullous formation, or bilirubin >15 mg/dL
☐ Not applicable (acute GVHD present but cannot be graded)

List the stage for each organ at diagnosis of acute GVHD:
23. Skin:

☐ Stage 0 – no rash, no rash attributable to acute GVHD
☐ Stage 1 – maculopapular rash, < 25% of body surface
☐ Stage 2 – maculopapular rash, 25-50% of body surface
☐ Stage 3 – generalized erythroderma, > 50% of body surface
☐ Stage 4 – generalized erythroderma with bullae formation and/or desquamation

24. Lower intestinal tract: (use mL/day for adult recipients and mL/kg/day for pediatric
recipients)

☐ Stage 0 – no diarrhea, no diarrhea attributable to acute GVHD / diarrhea < 500 mL/
day (adult), or < 10 mL/kg/day (pediatric)

☐ Stage 1 – diarrhea 500-1000 mL/day (adult), or 10-19.9 mL/kg/day (pediatric)
☐ Stage 2 – diarrhea 1001-1500 mL/day (adult), or 20-30 mL/kg/day (pediatric)
☐ Stage 3 – diarrhea > 1500 mL/day (adult), or > 30 mL/kg/day (pediatric)
☐ Stage 4 – severe abdominal pain, with or without ileus, and/or grossly bloody stool

25. Upper intestinal tract:

☐ Stage 0 – no persistent nausea or vomiting
☐ Stage 1 – persistent nausea or vomiting

CIBMTR Form 2450 revision 5 (page 6 of 16). Last Updated November, 2018.
Copyright (c) 2018 National Marrow Donor Program and
The Medical College of Wisconsin, Inc. All rights reserved.

CIBMTR Center Number: ___ ___ ___ ___ ___

CIBMTR Research ID: ___ ___ ___ ___ ___ ___ ___ ___ ___ ___

26. Liver:

☐ Stage 0 – no liver acute GVHD / bilirubin < 2.0 mg/dL (< 34 μmol/L)
☐ Stage 1 – bilirubin 2.0-3.0 mg/dL (34-52 μmol/L)
☐ Stage 2 – bilirubin 3.1-6.0 mg/dL (53-103 μmol/L)
☐ Stage 3 – bilirubin 6.1-15.0 mg/dL (104-256 μmol/L)
☐ Stage 4 – bilirubin > 15.0 mg/dL (> 256 μmol/L)

27. Other site(s) involved with acute GVHD

☐ Yes
☐ No

28. Specify other site(s):______________________________________

Specify the maximum overall grade and organ staging of acute GVHD since the date of
last report:
29. Maximum overall grade of acute GVHD:

☐ I - Rash on ≤ 50% of skin, no liver or gut involvement

☐ II - Rash on > 50% of skin, bilirubin 2-3 mg/dL, or diarrhea 500-1000 mL/day or
persistent nausea

☐ III - Bilirubin 3-15 mg/dL, or gut stage 2-4 diarrhea > 1000 mL/day or severe
abdominal pain with or without ileus

☐ IV - Generalized erythroderma with bullous formation, or bilirubin >15 mg/dL
☐ Not applicable (acute GVHD present but cannot be graded)
30. Date maximum overall grade of acute GVHD:

__ __ __ __ / __ __ / __ __
YYYY
MM
DD

31. Skin:

☐ Stage 0 – no rash, no rash attributable to acute GVHD
☐ Stage 1 – maculopapular rash, < 25% of body surface
☐ Stage 2 – maculopapular rash, 25–50% of body surface
☐ Stage 3 – generalized erythroderma, > 50% of body surface
☐ Stage 4 – generalized erythroderma with bullae formation and/or desquamation

32. Lower intestinal tract: (use mL/day for adult recipients and mL/kg/day for pediatric
recipients)

☐ Stage 0 – no diarrhea, no diarrhea attributable to acute GVHD / diarrhea < 500 mL/
day (adult), or < 10 mL/kg/day (pediatric)

☐ Stage 1 – diarrhea 500 - 1000 mL/day (adult), or 10 - 19.9 mL/kg/day (pediatric)
☐ Stage 2 – diarrhea 1001 - 1500 mL/day (adult), or 20 - 30 mL/kg/day (pediatric)
☐ Stage 3 – diarrhea > 1500 mL/day (adult), or > 30 mL/kg/day (pediatric)
☐ Stage 4 – severe abdominal pain, with or without ileus, and/or grossly bloody stool

33. Upper intestinal tract:

☐ Stage 0 – no persistent nausea or vomiting
☐ Stage 1 – persistent nausea or vomiting

CIBMTR Form 2450 revision 5 (page 7 of 16). Last Updated November, 2018.
Copyright (c) 2018 National Marrow Donor Program and
The Medical College of Wisconsin, Inc. All rights reserved.

CIBMTR Center Number: ___ ___ ___ ___ ___

CIBMTR Research ID: ___ ___ ___ ___ ___ ___ ___ ___ ___ ___

34. Liver:

☐ Stage 0 – No liver acute GVHD / bilirubin < 2.0 mg/dL (< 34 μmol/L)
☐ Stage 1 – bilirubin 2.0–3.0 mg/dL (34–52 μmol/L)
☐ Stage 2 – bilirubin 3.1–6.0 mg/dL (53–103 μmol/L)
☐ Stage 3 – bilirubin 6.1–15.0 mg/dL (104–256 μmol/L)
☐ Stage 4 – bilirubin > 15.0 mg/dL (> 256 μmol/L)

35. Other site(s) involved with acute GVHD

☐ Yes
☐ No

36. Specify other site(s): _________________________________

37. Did chronic GVHD develop since the date of last report?

☐ Yes
☐ No
☐ Unknown

38. Date of chronic GVHD diagnosis: __ __ __ __ / __ __ / __ __ ☐ Date estimated
YYYY
MM
DD - Go to question 40

39. Did chronic GVHD persist since the date of last report?

☐ Yes
☐ No
☐ Unknown

Specify the maximum grade of chronic GVHD since the date of last report:
40. Maximum grade of chronic GVHD: (according to best clinical judgment)

☐ Mild

☐ Moderate

☐ Severe

☐ Unknown

41. Specify if chronic GVHD was limited or extensive:

☐ Limited – localized skin involvement and/or liver dysfunction

☐ Extensive – one or more of the following:
– generalized skin involvement; or,
– liver histology showing chronic aggressive hepatitis, bridging necrosis or
cirrhosis; or,
– involvement of eye: Schirmer’s test with < 5 mm wetting; or
– involvement of minor salivary glands or oral mucosa demonstrated on labial
biopsy; or
– involvement of any other target organ
42. Date of maximum grade of chronic GVHD:

__ __ __ __ / __ __ / __ __
YYYY
MM
DD

43. Is the recipient still taking systemic steroids? (Do not report steroids for adrenal insufficiency, or steroid dose ≤10 mg/day for adults, <0.1 mg/

kg/day for children)

☐ Yes

☐ No

☐ Not applicable

☐ Unknown

44. Is the recipient still taking (non-steroid) immunosuppressive agents (including PUVA) for GVHD?

☐ Yes

☐ No

☐ Not applicable

☐ Unknown

CIBMTR Form 2450 revision 5 (page 8 of 16). Last Updated November, 2018.
Copyright (c) 2018 National Marrow Donor Program and
The Medical College of Wisconsin, Inc. All rights reserved.

CIBMTR Center Number: ___ ___ ___ ___ ___

CIBMTR Research ID: ___ ___ ___ ___ ___ ___ ___ ___ ___ ___

Liver Toxicity Prophylaxis
45. Was specific therapy used to prevent liver toxicity?

☐ Yes
☐ No

46. Specify therapy: (check all that apply)

☐ Defibrotide
☐ N-acetylcysteine
☐ Tissue plasminogen activator (TPA)
☐ Ursodiol

☐ Other therapy
47.
Specify other therapy:_________________________

Veno-occlusive disease (VOD) / Sinusoidal obstruction syndrome (SOS)
Specify if the recipient developed VOD / SOS since the date of last report:
48. Did veno-occlusive disease (VOD) / sinusoidal obstruction syndrome (SOS) develop since the date of last report?

☐ Yes
☐ No

49. Date of diagnosis: __ __ __ __ / __ __ / __ __

YYYY
MM
DD

New Malignancy, Lymphoproliferative or Myeloproliferative Disease / Disorder
Report new malignancies that are different than the disease / disorder for which HCT was performed. Do not include relapse, progression
or transformation of the same disease subtype.
50. Did a new malignancy, myelodysplastic, myeloproliferative, or lymphoproliferative disease / disorder occur that is different from the disease

/ disorder for which the HCT or cellular therapy was performed? (include clonal cytogenetic abnormalities, and post-transplant

lymphoproliferative disorders)

☐ Yes
☐ No

Copy and complete questions 51-57 to report each new malignancy diagnosed since the date of last
report. The submission of a pathology report or other supportive documentation for each reported new
malignancy is strongly recommended.
51. Specify the new malignancy

☐ Acute myeloid leukemia (AML / ANLL) - Go to question 54
☐ Other leukemia - Go to question 54
☐ Myelodysplastic syndrome (MDS) - Go to question 54
☐ Myeloproliferative neoplasm (MPN) - Go to question 54
☐ Myelodysplasia / myeloproliferative neoplasm (MDS / MPN) - Go to question 54
☐ Hodgkin lymphoma - Go to question 53
☐ Non-Hodgkin lymphoma - Go to question 53
☐ Post-transplant lymphoproliferative disorder (PTLD) - Go to question 53
☐ Clonal cytogenetic abnormality without leukemia or MDS - Go to question 54
☐ Uncontrolled proliferation of donor cells without malignant transformation - Go to question 54
☐ Breast cancer - Go to question 54
☐ Central nervous system (CNS) malignancy (e.g. glioblastoma, astrocytoma) - Go to question 54
☐ Gastrointestinal malignancy (e.g. colon, rectum, stomach, pancreas, intestine) - Go to question 54
☐ Genitourinary malignancy (e.g. kidney, bladder, ovary, testicle, genitalia, uterus, cervix)

- Go to question 54

☐ Lung cancer - Go to question 54

CIBMTR Form 2450 revision 5 (page 9 of 16). Last Updated November, 2018.
Copyright (c) 2018 National Marrow Donor Program and
The Medical College of Wisconsin, Inc. All rights reserved.

CIBMTR Center Number: ___ ___ ___ ___ ___

CIBMTR Research ID: ___ ___ ___ ___ ___ ___ ___ ___ ___ ___

☐ Melanoma - Go to question 54
☐ Basal cell skin malignancy - Go to question 54
☐ Squamous cell skin malignancy - Go to question 54
☐ Oropharyngeal cancer (e.g. tongue, buccal mucosa) - Go to question 54
☐ Sarcoma - Go to question 54
☐ Thyroid cancer - Go to question 54
☐ Other new malignancy - Go to question 52
52. Specify other new malignancy:

- Go to question 52

☐ Yes

53. Is the tumor EBV positive?

☐ No

54. Date of diagnosis: __ __ __ __ / __ __ / __ __

YYYY
MM
DD
55.

Was documentation submitted to the CIBMTR? (e.g. pathology / autopsy report or other documentation)

☐ Yes

☐ No

56. Was the new malignancy donor / cell product derived?

☐ Yes
☐ No
☐ Not done

57. Was documentation submitted to the CIBMTR? (e.g. cell origin evaluation (VNTR,

cytogenetics, FISH))

☐ Yes

☐ No

Chimerism Studies (Cord Blood Units, Beta Thalassemia, and Sickle Cell Disease Only)
This section relates to chimerism studies from allogeneic HCTs using cord blood units or for recipients whose primary disease is beta
thalassemia or sickle cell disease. If this was an autologous HCT, or an allogeneic HCT using a bone marrow or PBSC product, or a
different primary disease, continue to disease assessment.
58. Were chimerism studies performed since the date of last report?

☐ Yes
☐ No - Go to question 78

59. Was documentation submitted to the CIBMTR? (e.g. chimerism laboratory reports)

☐ Yes

☐ No

60. Were chimerism studies assessed for more than one donor / multiple donors?

☐ Yes

☐ No

Provide date(s), method(s) and other information for all chimerism studies performed since the date of last report.
61. NMDP donor ID: ___ ___ ___ ___ — ___ ___ ___ ___ — ___
62. NMDP cord blood unit ID: ___ ___ ___ ___ ___ ___ ___ ___ ___ ___
63. Non-NMDP unrelated donor ID: ___ ___ ___ ___ ___ ___ ___ ___ ___ ___
64. Non-NMDP cord blood unit ID: ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___
65. Global Registration Identifiers for Donors (GRID): __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ (optional)
66. Date of birth: (donor / infant) __ __ __ __ / __ __ / __ __ – OR – Age: (donor/infant) ___ ___ ☐ Months

YYYY
MM
DD
67. Sex (Donor / infant) ☐ Male
CIBMTR Form 2450 revision 5 (page 10 of 16). Last Updated November, 2018.
Copyright (c) 2018 National Marrow Donor Program and
The Medical College of Wisconsin, Inc. All rights reserved.

☐ Female

☐ Years

CIBMTR Center Number: ___ ___ ___ ___ ___

CIBMTR Research ID: ___ ___ ___ ___ ___ ___ ___ ___ ___ ___

68. Date sample collected: __ __ __ __ / __ __ / __ __

YYYY
MM
DD
69. Method

☐ Karyotyping for XX/XY

☐ Fluorescent in situ hybridization (FISH) for XX/XY
☐ Restriction fragment-length polymorphisms (RFLP)

☐ VNTR or STR, micro or mini satellite (Also include AFLP)

☐ Other

70. Specify:______________________________________________________________

71. Cell source

☐ Bone marrow

☐ Peripheral blood

72. Cell type

☐ Unsorted / whole - Go to question 74
☐ Red blood cells - Go to question 76
☐ Hematopoietic progenitor cells (CD34+ cells) - Go to question 76
☐ Total mononuclear cells (lymphs & monos) - Go to question 76
☐ T-cells (includes CD3+, CD4+, and/or CD8+) - Go to question 76
☐ B-cells (includes CD19+ or CD20+) - Go to question 76
☐ Granulocytes (includes CD33+ myeloid cells) - Go to question 76
☐ NK cells (CD56+) - Go to question 76
☐ Other

73. Specify:______________________________________________________________

74. Total cells examined: ___ ___ ___ ___ ___ ___
75. Number of donor cells: ___ ___ ___ ___ - Go to question 78
76. Were donor cells detected?

☐ Yes
☐ No

77. Percent donor cells: ___ ___ ___ %

Copy and complete questions 61-77 for multiple chimerism studies.

Disease Assessment at the Time of Best Response to HCT
78. Compared to the disease status prior to the preparative regimen, what was the best response to HCT since the date of the last report?

(Include response to any therapy given for post-HCT maintenance or consolidation, but exclude any therapy given for relapsed, persistent, or

progressive disease)

☐ Continued complete remission (CCR) - Go to question 101
☐ Complete remission (CR) - Go to question 80
☐ Not in complete remission - Go to question 79
☐ Not evaluated - Go to question 101

CIBMTR Form 2450 revision 5 (page 11 of 16). Last Updated November, 2018.
Copyright (c) 2018 National Marrow Donor Program and
The Medical College of Wisconsin, Inc. All rights reserved.

CIBMTR Center Number: ___ ___ ___ ___ ___

CIBMTR Research ID: ___ ___ ___ ___ ___ ___ ___ ___ ___ ___

79. Specify disease status if not in complete remission:

☐ Disease detected - Go to question 82

☐ No disease detected but incomplete evaluation to establish CR - Go to question 82

80. Was the date of best response previously reported?

☐ Yes - Go to question 101

☐ No

81. Date assessed: __ __ __ __ / __ __ / __ __

YYYY
MM
DD
Specify the method(s) used to assess the disease status at the time of best
response:
82. Was the disease status assessed by molecular testing (e.g. PCR)?

☐ Yes
☐ No
☐ Not applicable

83. Date assessed: __ __ __ __ / __ __ / __ __

YYYY
MM
DD
84.

Was disease detected? ☐ Yes

☐ No

85. Was the disease status assessed via flow cytometry?

☐ Yes
☐ No
☐ Not applicable

86.

Date assessed: __ __ __ __ / __ __ / __ __

YYYY
MM
DD
87.

Was disease detected? ☐ Yes

☐ No

88. Was the disease status assessed by cytogenetic testing (karyotyping or FISH)?

☐ Yes
☐ No
☐ Not applicable

89.

Was the disease status assessed via FISH?

☐ Yes
☐ No
☐ Not applicable

90.

Date assessed:

__ __ __ __ / __ __ / __ __
YYYY
MM
DD

91. Was disease detected?

☐ Yes

☐ No

92. Was the disease status assessed via karyotyping?

☐ Yes
☐ No
☐ Not applicable

93.

Date assessed:

__ __ __ __ / __ __ / __ __
YYYY
MM
DD

94. Was disease detected?

☐ Yes

CIBMTR Form 2450 revision 5 (page 12 of 16). Last Updated November, 2018.
Copyright (c) 2018 National Marrow Donor Program and
The Medical College of Wisconsin, Inc. All rights reserved.

☐ No

CIBMTR Center Number: ___ ___ ___ ___ ___

CIBMTR Research ID: ___ ___ ___ ___ ___ ___ ___ ___ ___ ___

95. Was the disease status assessed by radiological assessment? (e.g. PET, MRI, CT)

☐ Yes
☐ No
☐ Not applicable

96. Date assessed: __ __ __ __ / __ __ / __ __

YYYY
MM
DD
97. Was disease detected? ☐ Yes

☐ No

98. Was the disease status assessed by clinical / hematologic assessment?

☐ Yes
☐ No

99. Date assessed: __ __ __ __ / __ __ / __ __

YYYY
MM
DD
100. Was disease detected? ☐ Yes

☐ No

Post-HCT Therapy
Report therapy given since the date of last report to prevent relapse or progressive disease. This may include maintenance and
consolidation therapy. Do not report any therapy given for relapsed, persistent, or progressive disease.
101. Was therapy given since the date of the last report for reasons other than relapse, persistent, or progressive disease? (Include any

maintenance and consolidation therapy.)

☐ Yes
☐ No

102. Systemic therapy (check all that apply)

☐ Systemic therapy - Go to question 103
☐ Radiation
☐ Cellular therapy
☐ Blinded randomized trial
☐ Other therapy - Go to question 105
103. Specify systemic therapy: (check all that apply)

☐ Alemtuzumab (Campath)

☐ Azacytidine (Vidaza)

☐ Blinatumomab

☐ Bortezomib (Velcade)

☐ Bosutinib

☐ Carfilzomib

☐ Chemotherapy

☐ Dasatinib (Sprycel)

☐ Decitabine (Dacogen)

☐ Gemtuzumab (Mylotarg, anti-CD33)

☐ Gilteritinib

☐ Ibrutinib
☐ Imatinib mesylate (Gleevec)
☐ Ixazomib

☐ Lenalidomide (Revlimid)

☐ Lestaurtinib

CIBMTR Form 2450 revision 5 (page 13 of 16). Last Updated November, 2018.
Copyright (c) 2018 National Marrow Donor Program and
The Medical College of Wisconsin, Inc. All rights reserved.

CIBMTR Center Number: ___ ___ ___ ___ ___

CIBMTR Research ID: ___ ___ ___ ___ ___ ___ ___ ___ ___ ___

☐ Midostaurin
☐ Nilotinib (AMN107, Tasigna)
☐ Nivolumab
☐ Pembrolizumab
☐ Pomalidomide
☐ Quizartinib
☐ Rituximab (Rituxan, MabThera)
☐ Sorafenib
☐ Sunitinib
☐ Thalidomide (Thalomid)
☐ Other systemic therapy

104. Specify other systemic therapy:

___________________________

105. Specify other therapy:__________________________________________________

Relapse or Progression Post-HCT
Report if the recipient has experienced a clinical/hematologic relapse or progression post-HCT. If the relapse or progression was detected
in a previous reporting period indicate that and continue on. If the first clinical/hematologic relapse occurred since the date of last report,
indicate the date it was first detected in this reporting period.
106. Did the recipient experience a clinical/hematologic relapse or progression post-HCT?

☐ Yes
☐ No

107. Was the date of clinical/hematologic relapse or progression previously reported?

☐ Yes (only valid >day 100)
☐ No

108. Date first seen: __ __ __ __ / __ __ / __ __

YYYY
MM
DD

Intervention for relapsed disease, persistent disease, progressive disease, or decreased/loss of chimerism
109. Was intervention given for relapsed, persistent or progressive disease, or decreased/loss of chimerism since the date of last report?

☐ Yes
☐ No

110. Specify reason for which intervention was given:

☐ Persistent disease
☐ Relapsed / progressive disease

111. Specify the method(s) of detection for which intervention was given:

☐ Clinical/hematologic
☐ Radiological (e.g. PET, MRI, CT)
☐ Cytogenetic
☐ Flow cytometry
☐ Disease specific molecular marker

CIBMTR Form 2450 revision 5 (page 14 of 16). Last Updated November, 2018.
Copyright (c) 2018 National Marrow Donor Program and
The Medical College of Wisconsin, Inc. All rights reserved.

CIBMTR Center Number: ___ ___ ___ ___ ___

CIBMTR Research ID: ___ ___ ___ ___ ___ ___ ___ ___ ___ ___

112. Date intervention started: __ __ __ __ / __ __ / __ __

YYYY
MM
DD
113. Systemic therapy (check all that apply)

☐ Systemic therapy - Go to question 114
☐ Radiation
☐ Cellular therapy
☐ Blinded randomized trial
☐ Other therapy - Go to question 116
114. Specify system therapy: (check all that apply)

☐ Alemtuzumab (Campath)

☐ Azacytidine (Vidaza)

☐ Blinatumomab

☐ Bortezomib (Velcade)

☐ Bosutinib

☐ Carfilzomib

☐ Chemotherapy Dasatinib (Sprycel)

☐ Dasatinib (Sprycel)

☐ Decitabine (Dacogen)

☐ Gemtuzumab (Mylotarg, anti-CD33)

☐ Gilteritinib

☐ Ibrutinib
☐ Imatinib mesylate (Gleevec)
☐ Ixazomib

☐ Lenalidomide (Revlimid)

☐ Lestaurtinib

☐ Midostaurin

☐ Nilotinib (AMN107, Tasigna)

☐ Nivolumab

☐ Pembrolizumab

☐ Pomalidomide

☐ Quizartinib

☐ Rituximab (Rituxan, MabThera)

☐ Sorafenib

☐ Sunitinib

☐ Thalidomide (Thalomid)

☐ Other systemic therapy

115. Specify other systemic therapy:

___________________________

116. Specify other therapy:__________________________________________________

CIBMTR Form 2450 revision 5 (page 15 of 16). Last Updated November, 2018.
Copyright (c) 2018 National Marrow Donor Program and
The Medical College of Wisconsin, Inc. All rights reserved.

CIBMTR Center Number: ___ ___ ___ ___ ___

CIBMTR Research ID: ___ ___ ___ ___ ___ ___ ___ ___ ___ ___

Current Disease Status
117. What is the current disease status?

☐ Complete remission (CR) - Go to question 119
☐ Not in complete remission - Go to question 118
☐ Not evaluated - Go to signature line
118. Specify disease status if not in complete remission:

☐ Disease detected

☐ No disease detected but incomplete evaluation to establish CR

119. Date of most recent disease assessment

☐ Known
☐ Unknown

120. Date of most recent disease assessment: __ __ __ __ / __ __ / __ __

YYYY
MM
DD

First Name:_____________________________________________________
Last Name:______________________________________________________
E-mail address:__________________________________________________
Date: __ __ __ __ / __ __ / __ __
YYYY
MM
DD

CIBMTR Form 2450 revision 5 (page 16 of 16). Last Updated November, 2018.
Copyright (c) 2018 National Marrow Donor Program and
The Medical College of Wisconsin, Inc. All rights reserved.